Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $23.12, but opened at $20.01. Pharvaris shares last traded at $20.95, with a volume of 166,855 shares.
Wall Street Analysts Forecast Growth
PHVS has been the subject of a number of research reports. Cantor Fitzgerald dropped their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Guggenheim initiated coverage on Pharvaris in a research note on Wednesday, June 11th. They issued a "buy" rating and a $32.00 price target for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a research note on Thursday, June 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $36.20.
Read Our Latest Report on Pharvaris
Pharvaris Price Performance
The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -6.85 and a beta of -2.82. The stock has a fifty day moving average of $18.41 and a two-hundred day moving average of $16.94.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). On average, research analysts forecast that Pharvaris N.V. will post -2.71 EPS for the current year.
Institutional Trading of Pharvaris
A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new position in Pharvaris in the 4th quarter valued at about $64,000. KLP Kapitalforvaltning AS bought a new position in Pharvaris in the 4th quarter valued at about $111,000. Point72 Asset Management L.P. bought a new position in Pharvaris in the 4th quarter valued at about $152,000. Finally, Legal & General Group Plc lifted its position in Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after acquiring an additional 994 shares in the last quarter.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
